Immunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology™. IP-001, the first asset from the company’s intellectual property platform, has the potential to overcome the local defenses of the tumor microenvironment to enable a tumor-specific anticancer immune response in multiple solid tumor indications. The company is in phase 2 development and is headquartered in St. Louis, Missouri, USA.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Missouri
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Oncology
Lead Product in Development:
IP-001 a proprietary glycan polymer
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
